VEGFA and nasopharyngeal carcinoma: Our study indicates that a combination of miR-23a inhibitor with currently available VEGF inhibitors would better clarify the disease traits at the individual level; this leads, in turn, to enhance our ability to take preventive treatment for NPC patients with a high risk of metastasis.